Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VR-CAP versus R-CHOP in newly diagnosed non-germinal center diffuse large B-cell lymphoma
2009-012280-34Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone and 1 more in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Complete response rate. Started Oct 2009; status: completed.
02
Drugs
bortezomibrituximabcyclophosphamidedoxorubicinprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2009-012280-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012280-34.